AmerisourceBergen Corporation ABC today announced that it has signed a
definitive agreement to sell its Canadian pharmaceutical distribution
business, AmerisourceBergen Canada Corporation (ABCC), to Kohl & Frisch
Limited, a Canadian-owned national full-line distributor. The transaction is
expected to close in the third quarter of fiscal 2013, and is subject to
customary closing conditions, including certain regulatory approvals.
AmerisourceBergen will retain its Canadian specialty business.
The estimated sale price is expected to be between $80 million and $100
million, of which approximately half will be financed by AmerisourceBergen. As
a result of the agreement, the Company expects to record an estimated loss on
sale and other impairment charges of between $160 million and $180 million
when it reports its quarterly results for the March quarter of fiscal 2013.
This estimated loss on sale, in addition to ABCC's operating losses, will be
reported within discontinued operations. ABCC represented approximately 2
percent of AmerisourceBergen's total revenues.
Due to the impact of the sale, AmerisourceBergen has revised its financial
performance expectations for fiscal year 2013. The Company now expects revenue
growth in the range of 8 to 10 percent and it has increased its estimated
earnings per share from continuing operations for fiscal 2013 from a range of
$2.96 to $3.06 to a range of $3.04 to $3.14. The revised earnings per share
range does not include the impact of significant one-time expenses anticipated
as a result of the previously disclosed new strategic long-term relationship
with Walgreen Co. and Alliance Boots, GmbH, including a LIFO expense due to an
anticipated inventory build and recurring non-cash expenses relating to the
equity warrants issued in connection with the new relationship. The Company
continues to expect free cash flow in the range of $100 million to $200
million, and to repurchase approximately $400 million of common stock in
fiscal 2013.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in